# About Legal NAD: An Editorial Digest of the NAD+ Research

> Legal NAD is an independent editorial project summarizing the peer-reviewed NAD+ research. Not a clinic, not a vendor — a signal-clean readout of the coenzyme and precursor literature.

Who publishes this, what it is, and — just as important — what it is not.

## What Legal NAD is

Legal NAD is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on NAD+ and its precursors. We read the studies, log what they measured, tag each finding by route and by evidence strength, and cite every figure to source. The format is deliberately an instrument readout rather than an opinion column: confirmed findings, preclinical signals, and honest gaps, each in its own panel.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

## What the name means

The word 'legal' in the name is editorial framing, not a claim about services or a legal opinion. It points at a real feature of this subject: NAD+ and its common precursors are sold as dietary supplements rather than approved drugs, and the regulatory status of one precursor — NMN — is genuinely contested in the U.S. marketplace [13]. The name marks the position this publisher occupies relative to that literature — reading the supplement-and-regulatory record straight — not a service we offer. We do not sell NAD+, advise on buying it, or operate any pathway to obtain it.

## How we handle accuracy

Two disciplines govern every page. First, the NAD+-versus-precursor distinction is kept exact: oral NAD+ is poorly absorbed, so a trial of NMN or NR is never described as 'taking NAD+', and every route-specific figure carries a channel tag (ORAL-PRECURSOR, IV, INJECTABLE). Second, we describe only what specific cited studies measured, in research framing — 'a trial of `250 mg/day` NMN raised blood NAD+ and improved muscle insulin sensitivity' [11] — never a recommendation to use any product or dose. We do not claim NAD+ or any precursor treats, reverses, cures or prevents aging or any disease. Where the evidence is thin — IV NAD+, hard clinical endpoints, tissue-level NAD+ — we say so, citing the 2025 review that reached the same conclusion [14].

## Corrections

If a citation is misattributed or a figure is wrong, we want to fix it. The studies cited here are real, indexed and linked; if you find an error, the contact page is the way to flag it. This is a digest of the literature, and the literature is the authority — not this site.

---

A signal-clean readout of the NAD+ literature — the precursor trials that actually moved whole-blood NAD+ logged in their own oral channel, plain oral NAD+ and the weak-evidence IV route kept on separate channels, and the unsettled NMN status reported as filed; no clinic behind this console and nothing here dosed, dispensed, or sold.